| 摘要 |
The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a PDE-4 inhibitor, a PDE-5 inhibitor, a compound that elevates cGMP and/or PKG, a stimulator of guanylyl cyclase and/or PKG, a combination of a compound that elevates cGMP, PKG or NO with an antioxidant that decreases ROS, or a compound that increases MMP activity. |
| 主权项 |
1. A method comprising administering a cyclic guanosine 3′,5′-monophosphate (cGMP) type 5 phosphodiesterase (PDE-5) inhibitor according to a continuous, long-term regimen to an individual with at least one of a penile tunical fibrosis and corporal tissue fibrosis, wherein the PDE-5 inhibitor is selected from the group consisting of sildenafil, tadalafil, and vardenafil, wherein the PDE-5 inhibitor is administered at a dosage of up to 1.5 mg/kg/day, and wherein the PDE′″5 inhibitor is administered for greater than or equal to 45 days. |
